FDA Internet Enforcement Without Guidance May Create "Incongruity" - Lilly
Executive Summary
FDA's decision to halt work on an Internet guidance could result in enforcement "incongruity," Lilly Associate Internet Consultant Michael Pozsgai told a Drug Information Association conference in Washington D.C. Nov. 3.
You may also be interested in...
CDER Compliance Office Redesign Includes Internet, Risk Management Focus
The FDA Center for Drug Evaluation & Research's reorganized Office of Compliance includes a team focused on illegal sale of OTC and prescription drugs on the Internet
Pharmaceutical Website Links Receiving FDA Scrutiny, Ad Division Says
FDA's advertising division is examining the content of sites to which pharmaceutical product websites provide links.
Pharmaceutical Website Links Receiving FDA Scrutiny, Ad Division Says
FDA's advertising division is examining the content of sites to which pharmaceutical product websites provide links.